Options market pricing suggests Edwards Lifesciences Corp. may see about a 5% change in its share price when it issues its earnings on July 23 after the market closes, according to Bloomberg-derived options data.
That implied move reflects how traders are positioning ahead of the medical device maker's report. But past earnings outcomes show the options-implied figure has not always been a reliable predictor of the actual price reaction.
Across the last eight reported quarters cited, Edwards has outpaced the move implied by options in three instances. In the most recent quarter referenced, the April 23 release produced a 7.6% change in the stock while options had signaled a 6.7% swing.
Other past earnings results show a mix of alignment and divergence from options expectations. Examples from the record provided include:
- February 10: The stock declined 4.0% following the announcement, compared with an options-implied move of 5.7%.
- October 30, 2025: The actual price change was 7.3%, which matched the options-implied movement exactly.
- July 24, 2024: The largest gap recorded, when shares fell 32.0% despite options data implying a move of 5.7%.
- July 24, 2025: Shares rose 5.1%, against an implied move of just 0.9%.
- April 23, 2025: The stock moved 6.2%, while options had suggested an 8.0% move.
- February 11, 2025: The share price moved 6.2%, matching the options-implied move for that release.
- October 24, 2024: The stock moved only 1.6%, despite an implied move of 10.2% from options.
Those historical results illustrate that while options-implied moves provide a market consensus of expected volatility around earnings, actual reactions can be materially different. In some quarters the options signal has underestimated volatility; in others it has overestimated the outcome.
For traders and investors focused on Edwards, the options-implied 5% figure for July 23 offers a benchmark for potential short-term price movement, but the company’s past record shows sizable outliers are possible. Market participants may use the implied move as one input among several when assessing risk and positioning ahead of the report.
Bottom line: Options markets are pricing in roughly a 5% post-earnings move for Edwards Lifesciences on July 23 after the close, but historical comparisons show that actual price reactions have sometimes been much larger or smaller than what options implied.